Paper2199065
Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro.
Schumacher TN and 5 others. Cell, 1990. Cited by 448 papers, by iCite.
Cite this record
ConductScience Library. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Papers, record 2199065. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2199065
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Histocompatibility Antigens Class I | Major topic |
| Animals | |
| Cell Line | |
| Cell Membrane | |
| Electrophoresis, Polyacrylamide Gel | |
| H-2 Antigens | |
| Immunoenzyme Techniques | |
| Mice | |
| Peptides | |
| Protein Binding |
Source PubMed
Cited by124
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 448 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42646732 | Immunoinformatics-Driven Rational Design of Altered Peptide Ligands and In Vitro Validation of a Multi-Epitope CTL Formulation Targeting HPV16 E6/E7. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/42646732 | PubMed |
| 42191216 | Systematic Evaluation of Peptidomimetic Modifications in a Major Histocompatibility Complex Class I Model Epitope: A Framework for Immunogenic Antigen Design. | ACS Chem Biol | 2026 | https://conductscience.org/library/papers/42191216 | PubMed |
| 41726884 | A Framework for Comparing Mouse Neoantigen Immunogenicity. | bioRxiv | 2026 | https://conductscience.org/library/papers/41726884 | PubMed |
| 40091029 | IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40091029 | PubMed |
| 39150956 | A Chemical Approach to Assess the Impact of Post-translational Modification on MHC Peptide Binding and Effector Cell Engagement. | ACS Chem Biol | 2024 | https://conductscience.org/library/papers/39150956 | PubMed |
| 38930438 | Immunogenicity Analysis and Identification of Potential T-Cell Epitopes in C129R Protein of African Swine Fever Virus. | Microorganisms | 2024 | https://conductscience.org/library/papers/38930438 | PubMed |
| 38665920 | Targeted acidosis mediated delivery of antigenic MHC-binding peptides. | Front Immunol | 2024 | https://conductscience.org/library/papers/38665920 | PubMed |
| 38426497 | Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines. | J Clin Invest | 2024 | https://conductscience.org/library/papers/38426497 | PubMed |
| 38239352 | MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection. | Front Immunol | 2023 | https://conductscience.org/library/papers/38239352 | PubMed |
| 37310998 | Universal open MHC-I molecules for rapid peptide loading and enhanced complex stability across HLA allotypes. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37310998 | PubMed |
| 36722462 | Endo-lysosomal assembly variations among human leukocyte antigen class I (HLA class I) allotypes. | Elife | 2023 | https://conductscience.org/library/papers/36722462 | PubMed |
| 36134954 | Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis. | Antibodies (Basel) | 2022 | https://conductscience.org/library/papers/36134954 | PubMed |
| 35651601 | Molecular Determinants Regulating the Plasticity of the MHC Class II Immunopeptidome. | Front Immunol | 2022 | https://conductscience.org/library/papers/35651601 | PubMed |
| 35647522 | Homotypic and heterotypic in cis associations of MHC class I molecules at the cell surface. | Curr Res Immunol | 2022 | https://conductscience.org/library/papers/35647522 | PubMed |
| 35087915 | A Combinatorial in-silico, in-vitro and in-vivo Approach to Quantitatively Study Peptide Induced MHC Stability. | Bio Protoc | 2021 | https://conductscience.org/library/papers/35087915 | PubMed |
| 34534464 | Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. | Cell | 2021 | https://conductscience.org/library/papers/34534464 | PubMed |
| 34205517 | Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg. | Vaccines (Basel) | 2021 | https://conductscience.org/library/papers/34205517 | PubMed |
| 33963786 | Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes. | Adv Mater | 2021 | https://conductscience.org/library/papers/33963786 | PubMed |
| 33476307 | Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. | J Clin Invest | 2021 | https://conductscience.org/library/papers/33476307 | PubMed |
| 31201791 | MHC-I peptide binding activity assessed by exchange after cleavage of peptide covalently linked to β2-microglobulin. | Anal Biochem | 2019 | https://conductscience.org/library/papers/31201791 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2199065
GET https://conductscience.org/api/papers/v1/2199065/cited_by?page=2